The recent first global approval of durvalumab has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1] based on the development milestones tracked in AdisInsight.[2] Continue reading “Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer”
The recent First Global Approval[1] of baricitinib in the EU has been reviewed in detail in the First Global Approval report in Adis journal Drugs[2] based on the development milestones tracked in AdisInsight.[3] Continue reading “Baricitinib (Olumiant™): Follow up Approval in Japan (but not yet USA)”
The first global approval of sarilumab in Canada has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Sarilumab (Kevzara™): Follow up Approvals in US and Europe”
– Editors reinforce the critical role of patient involvement in decision-making around access to the medicines and health technologies they may need – Continue reading “The world’s first book dedicated to patient involvement in health technology assessment launched”